CompuGroup Medical SE

  • WKN: 543730
  • ISIN: DE0005437305
  • Land: Deutschland

Nachricht vom 11.02.2019 | 10:48

CompuGroup Medical SE: Release of a capital market information

CompuGroup Medical SE / Share Buyback

11.02.2019 / 10:48
Dissemination of a Post-admission Duties announcement transmitted by DGAP -
a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


CompuGroup Medical SE: Disclosure pursuant to Art. 5 Para. 1 lit. b) and Para. 3 of the Regulation (EU) No 596/2014 (MAR) in conjunction with Art. 2 Para. 2 and Para. 3 of the Commission Delegated Regulation (EU) No 2016/1052 - 8th Interim Announcement CompuGroup Medical SE / Share Buyback Koblenz, February 11 2019 CompuGroup Medical SE: Disclosure pursuant to Art. 5 Para. 1 lit. b) and Para. 3 of the Regulation (EU) No 596/2014 (MAR) in conjunction with Art. 2 Para. 2 and Para. 3 of the Commission Delegated Regulation (EU) No 2016/1052 - 8th Interim Announcement In the period from February 4, 2019, up to and including February 8, 2019, CompuGroup Medical SE has bought back a total of 35,417 shares of CompuGroup Medical SE within the framework of the share buyback program. In the announcement of December 14, 2018, pursuant to Art. 2 para. 1 of the Commission Delegated Regulation (EU) 2016/1052 supplementing Regulation (EU) No 596/2014 (MAR) it was communicated that the repurchase of treasury shares would commence on December 17, 2018. The overall volume of the shares bought back daily in the period from February 4, 2019, up to and including February 8, 2019, and the daily volume-weighted average stock market prices of the shares are as follows:

Date                   Overall volume of      Volume-weighted average
                       shares bought back     stock market price
                       (number)               (EUR, excluding ancillary
                                              costs of purchase, rounded
                                              to four places according to
                                              commercial practice)
February 4, 2019       2,534                  47.5930
February 5, 2019       7,021                  48.2803
February 6, 2019       6,400                  48.7610
February 7, 2019       10,812                 48.8011
February 8, 2019       8,650                  48.6587
In total:              35,417                 48,5694


The total number of shares which have been bought back so far by CompuGroup Medical SE since December 17, 2018, up to and including February 8, 2019, within the framework of the share buyback program thus amounts to 223,989 no-par value shares. Further information pursuant to Art. 5 para. 1 lit. b) and para. 3 of the Regulation (EU) No 596/2014 (MAR) in conjunction with Art. 2 para. 2 and para. 3 of the Commission Delegated Regulation (EU) No 2016/1052 is available online under https://www.cgm.com/sbb. The purchase of the shares of CompuGroup Medical SE was carried out by a bank assigned by CompuGroup Medical SE and exclusively via the Frankfurt Stock Exchange (Xetra trading). Koblenz, February 11, 2019 The Management Board CompuGroup Medical SE Investor Relations Maria Trost 21 56070 Koblenz, Germany T: 49 (0) 261 8000-6200 F: 49 (0) 261 8000-3200
11.02.2019 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
Language: English Company: CompuGroup Medical SE Maria Trost 21 56070 Koblenz Germany Internet: www.cgm.com End of News DGAP News Service

Interview im Fokus

HanseYachts: „Der ideale Zeitpunkt für den Kauf“

Die Übernahme des Katamaran-Herstellers Privilège bringt die HanseYachts AG dem Umsatzziel von 200 Mio. Euro einen bedeutenden Schritt näher. „Der Katamaran-Markt ist das derzeit am stärksten wachsende Segment im Yacht-Geschäft. Privilège ist weltweit in Preis und Qualität die Nummer eins“, so CEO Dr. Jens Gerhardt. Zudem sei der Deal ein wichtiger Faktor, um die EBITDA-Marge auf 10 bis 12 % zu steigern. Im Financial.de-Interview spricht der Konzernlenker über die aktuellsten Trends im Yacht-Geschäft, die laufende Barkapitalerhöhung sowie die Weltpremieren in Cannes.

GBC-Fokusbox

Fonds Research 2019: S.E.A. Asian High Yield Bond bietet attraktive Investitionschance

Auch 2019 hat die GBC AG unter der Vielzahl an Publikumsfonds neun „Fonds Champions“ herausgefiltert. Darunter auch den S.E.A. Asian High Yield Bond (ISIN: LU1138637738), der eine gute Anlagechance anbietet mit einer Strategie, die kaum reproduzierbar ist. Insbesondere vor dem Hintergrund des anhaltenden Niedrigzinsniveaus sehen wir den Anleihefonds als äußerst attraktive Investitionschance, um nachhaltige und volatilitätsarme Renditen zu erzielen. Wir haben den S.E.A. Asian High Yield Bond mit 4 von 5 Falken eingestuft.

Aktueller Webcast

SeaChange Corporation

Second Quarter 2020 Earnings Conference Call

29. August 2019

Aktuelle Research-Studie

ad pepper media International N.V.

Original-Research: ad pepper media International N.V. (von First Berlin Equity Research GmbH): Buy

23. August 2019